Last reviewed · How we verify
NCT06663748
ARX788 in HER2-positive Metastatic Breast Cancer Patients
Phase 2 trial testing ARX788 in HER2-positive, Metastatic Breast Cancer in 44 participants. Not yet recruiting.
20 November 2025
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 20 November 2024 |
| Primary completion | 20 November 2025 |
| Estimated completion | 20 November 2029 |
Drugs / interventions tested
- ARX788 — full drug profile →
Conditions studied
- HER2-positive, Metastatic Breast Cancer — all drugs for HER2-positive, Metastatic Breast Cancer →
Sponsor
Henan Cancer Hospital
Who can join
Adults 18 to 75, any sex, with HER2-positive, Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention.
Lei H, Fu J, Gu W, Qiao H, et al · · 2026 · PMID 41510186 · DOI 10.1002/mco2.70560
Verify or expand the search:
- PubMed search for NCT06663748
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ARX788
Trials testing the same drug.
- NCT06224673 — ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer · Phase 2 · not yet recruiting
- NCT06578286 — ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd · Phase 2 · not yet recruiting
- NCT05426486 — A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplat · Phase 2, PHASE3 · active not recruiting
- NCT05041972 — ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) · Phase 2 · withdrawn
- NCT05018676 — ARX788 in Breast Cancer With Low Expression of HER2 · Phase 2 · unknown
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06663748 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 29 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06663748.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing